Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Glaukos Corporation stands seventh among them.

Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapies, continues to expand its presence in glaucoma, corneal disorders, and retinal diseases through innovative “dropless” treatment platforms. Its FDA-approved iDose sustained-release implant delivers continuous glaucoma therapy directly inside the eye, improving patient adherence and outcomes.

In 2025, the company reported robust growth, with Q2 net sales up 30% year-over-year to $124.1 million. U.S. glaucoma treatment sales reached $72.3 million in the quarter, prompting the company to raise full-year guidance to $480-$486 million. This growth reflects strong adoption of the iDose TR implant and increasing market penetration. Despite being listed among the most oversold stocks recently, GKOS has continued to deliver strong operational performance

Glaukos Corporation (NYSE:GKOS) is also advancing its pipeline with next-generation therapies. The iDose TREX implant, in Phase 2b/3 trials, aims to extend treatment duration and improve compliance, while ongoing trials for iStent Infinite and PRESERFLO devices broaden the business’s long-term growth potential.

Glaukos Corporation (NYSE:GKOS)’s Epioxa, a non-invasive epi-on corneal cross-linking therapy for keratoconus, received FDA acceptance for review with a PDUFA date of October 20, 2025. If approved, it would be the first therapy of its kind not requiring corneal epithelium removal, offering shorter recovery times and enhanced patient comfort.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.